MRK · News · 20260908N
Competition and Market Share
Merck & Co., Inc. · 2026-09-08 · Importance 26 · Surprise 24 · In source text
Merck’s Enflonsia is entering the pediatric RSV-protection market against Sanofi and AstraZeneca’s Beyfortus. Beyfortus generated €1.8 billion in sales last year and is reinforcing its market position through consumer marketing ahead of the RSV season. The competitive launch environment could affect Merck’s ability to establish Enflonsia among pediatricians, parents, and other healthcare customers.
Key facts
- Sanofi's Beyfortus faces impending competition from Merck's Enflonsia (article states Enflonsia as upcoming competition). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Sanofi's Beyfortus faces impending competition from Merck's Enflonsia (article states Enflonsia as upcoming competition). |